Michael K. Laidlaw
Research Subjects
Michael K. Laidlaw has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andre Van Mol
Department of Family Practice, Andre Van Mol Private Practice, Redding, CA 96003, USA
2 shared publications - Quentin Van Meter
Department of Pediatric Endocrinology, Quentin Van Meter Pediatric Endocrinology P.C., Atlanta, GA 30318, USA
2 shared publications Andre Van Mol
Family Practice, Dignity Health Medical Group North State, Redding, Calif. (Van Mol); Michael K. Laidlaw, M.D., Inc., Rocklin, Calif. (Laidlaw); Miriam Grossman, M.D., Psychiatry, New York (Grossman); Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore (McHugh)
1 shared publicationAngela Thompson
Department of Obstetrics and Gynecology, St. Joseph Hospital, United States
1 shared publication- E Hansen
Department of Pediatric and Adolescent Clinical Psychology, Center for Connected Living LLC, Olympia, WA 98502, USA
1 shared publication Jennifer Lahl
Department of Bioethics and Culture, Center for Bioethics & Culture Network, United States
1 shared publication
Latest Publications
- Open Access
- 11 April 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1386716
Fertility preservation: is there a model for gender-dysphoric youth?
Assisted reproductive technologies (ART) and cryobiology advances over the past decades have offered hope to cancer patients who might not otherwise be able to have biological offspring due to the toxic nature of therapies that may lead to subfertility or infertility. Fertility preservation (FP) for youths with gender dysphoria (GD) poses an additional set of complications and obstacles because of the use of medications which block normal pubertal development such as gonadotropin-releasing hormone analogues (GnRHa) and medications which directly alter the genital tract such as cross sex hormones. Here we review the current state of knowledge and ethical concerns with FP focusing on issues when FP is used during adolescent and preadolescent reproductive development in the context of cancer and gender dysphoria treatment. Particularly for youths with GD, very little evidence-based research has been performed and much remains unknown with respect to long term harms to reproductive health and the ultimate success of FP and conception.
- 11 April 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1386716
Open AccessFertility preservation: is there a model for gender-dysphoric youth?
Assisted reproductive technologies (ART) and cryobiology advances over the past decades have offered hope to cancer patients who might not otherwise be able to have biological offspring due to the toxic nature of therapies that may lead to subfertility or infertility. Fertility preservation (FP) for youths with gender dysphoria (GD) poses an additional set of complications and obstacles because of the use of medications which block normal pubertal development such as gonadotropin-releasing hormone analogues (GnRHa) and medications which directly alter the genital tract such as cross sex hormones. Here we review the current state of knowledge and ethical concerns with FP focusing on issues when FP is used during adolescent and preadolescent reproductive development in the context of cancer and gender dysphoria treatment. Particularly for youths with GD, very little evidence-based research has been performed and much remains unknown with respect to long term harms to reproductive health and the ultimate success of FP and conception.
- 18 September 2024
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (5) , 491-492
Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database
- 18 September 2024
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 59 (5) , 491-492
Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database
- Open Access
- 23 July 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (12) , E5275-E5276
Letter to the Editor from Laidlaw et al: “Erythrocytosis in a Large Cohort of Transgender Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years”
Although it is laudable to attempt to quantify the risk of erythrocytosis due to the administration of exogenous testosterone to transgender males, the methodol
- 23 July 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (12) , E5275-E5276
Open AccessLetter to the Editor from Laidlaw et al: “Erythrocytosis in a Large Cohort of Transgender Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years”
Although it is laudable to attempt to quantify the risk of erythrocytosis due to the administration of exogenous testosterone to transgender males, the methodol
- 1 August 2020
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 177 (8) , 765-766
Gender-Affirmation Surgery Conclusion Lacks Evidence
- 1 August 2020
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 177 (8) , 765-766
Gender-Affirmation Surgery Conclusion Lacks Evidence
- 20 February 2019
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 19 (2) , 75-77
The Right to Best Care for Children Does Not Include the Right to Medical Transition
(2019). The Right to Best Care for Children Does Not Include the Right to Medical Transition. The American Journal of Bioethics: Vol. 19, No. 2, pp. 75-77.
- 20 February 2019
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 19 (2) , 75-77
The Right to Best Care for Children Does Not Include the Right to Medical Transition
(2019). The Right to Best Care for Children Does Not Include the Right to Medical Transition. The American Journal of Bioethics: Vol. 19, No. 2, pp. 75-77.
- 23 November 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (3) , 686-687
Letter to the Editor: “Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline”
Michael K Laidlaw, Quentin Van Meter, Paul W Hruz, Andre Van Mol, William J Malone; Letter to the Editor: “Endocrine Treatment of Gender-Dysphoric/Gender-Incon
- 23 November 2018
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (3) , 686-687
Letter to the Editor: “Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline”
Michael K Laidlaw, Quentin Van Meter, Paul W Hruz, Andre Van Mol, William J Malone; Letter to the Editor: “Endocrine Treatment of Gender-Dysphoric/Gender-Incon